Get the latest news on Accustem Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on ACUT performance

Latest Accustem Sciences Stock News | OTC:ACUT | Benzinga

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

ACUT

AUGG

BJDX

RYES

US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Stocks Under $2 Insiders Are Aggressively Buying

ACCUSTEM SCIENCES INC by Accustem Sciences Inc.

Accustem Sciences Inc

ACUTUS MEDICAL INC by Acutus Medical Inc.

Acutus Medical Inc

Press Releases

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Accustem Sciences

US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.

<h2>Bluejay Diagnostics </h2>

<ul>
	<li>The Trade: Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) Chief Financial Officer Kenneth Fisher <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $0.99. To acquire these shares, it cost $19.8 thousand.</li>
	<li>What&rsquo;s Happening: Bluejay Diagnostics recently posted a Q1 loss of $0.10 per share.</li>
	<li>What Bluejay Diagnostics Does: Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.</li>
</ul>

<h2>Rise Gold </h2>

<ul>
	<li>The Trade: Rise Gold Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RYES#OTC">RYES</a>) Director Lawrence W. Lepard <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 216,500 shares </a> at an average price of $0.51. The insider spent around $110.59 thousand to buy those shares.</li>
	<li>What&rsquo;s Happening: Rise Gold recently reported progress on Idaho-Maryland use permit.</li>
	<li>What Rise Gold Does: Rise Gold Corp is a mineral exploration stage mining company and its primary asset is a major past producing Idaho-Maryland Gold Mine property near Grass Valley, California, United States.</li>
</ul>

<a href="https://www.benzinga.com/trading-ideas/long-ideas/22/04/26834505/executives-buy-around-413m-of-3-stocks">Also check this: Executives Buy Around $413M Of 3 Stocks </a>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>.

<h2>Augusta Gold </h2>

<ul>
	<li>The Trade: Augusta Gold Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUGG#OTC">AUGG</a>) Director Augusta Investments Inc <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 22,500 shares </a> at an average price of $1.14. To acquire these shares, it cost around $25.61 thousand.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s stock has gained 35% since the start of the year.</li>
	<li>What Augusta Gold Does: Augusta Gold Corp is an exploration stage company. The company is primarily engaged in the acquisition and exploration of gold properties.</li>
</ul>

<h2>Accustem Sciences </h2>

<ul>
	<li>The Trade: Accustem Sciences Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACUT#OTC">ACUT</a>) Director Gabriele M Cerrone <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 9,447 shares </a> at an average price of $1.43. The insider spent $13.49 thousand to buy those shares.</li>
	<li>What&rsquo;s Happening: AccuStem recently reported a private placement of common stock.</li>
	<li>What Accustem Sciences Does: Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe.</li>
</ul>

Comments

Accustem Sciences Stock News

News

Latest Accustem Sciences Stock News | OTC:ACUT | Benzinga

Thursday, April 28, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga